

## REFERENCES

- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future national survey results on drug use, 1975-2010. Volume I: secondary school students. Ann Arbor, MI. Institute for Social Research, The University of Michigan; 2011.
- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future national survey results on drug use, 1975-2010. Volume II: college students and adults ages 19-50. Ann Arbor, MI. Institute for Social Research, The University of Michigan; 2011.
- Milroy CM: "Ecstasy" associated deaths: what is a fatal concentration? Analysis of a case series. *Forensic Sci Med Pathol* 7: 248, 2011.
- Hill SL, Thomas SH: Clinical toxicology of newer recreational drugs. *Clin Toxicol (Phila)* 49: 705, 2011.
- Peet M, Peters S: Drug-induced mania. *Drug Saf* 12: 146, 1995.
- Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M: Adulterants in illicit drugs: a review of empirical evidence. *Drug Test Anal* 3: 89, 2011.
- Tanner-Smith EE: Pharmacological content of tablets sold as "ecstasy": results from an online testing service. *Drug Alcohol Depend* 83: 247, 2006.
- Mathias S, Lubman DI, Hides L: Substance-induced psychosis: a diagnostic conundrum. *J Clin Psychiatry* 69: 358, 2008.
- Caton CL, Drake RE, Hasin DS, et al: Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. *Arch Gen Psychiatry* 62: 217, 2005.
- Gable RS: Comparison of acute lethal toxicity of commonly abused psychoactive substances. *Addiction* 99: 686, 2004.
- Abraham HD, Aldridge AM, Gogia P: The psychopharmacology of hallucinogens. *Neuropharmacology* 14: 285, 1996.
- Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A: The pharmacology of lysergic acid diethylamide: a review. *CNS Neurosci Ther* 14: 295, 2008.
- Blaho K, Merigian K, Winbery S, Geraci SA, Smartt C: Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication. *Am J Ther* 4: 211, 1997.
- Berrens Z, Lammers J, White C: Rhabdomyolysis after LSD ingestion. *Psychosomatics* 51: 356, e3, 2010.
- Klock JC, Boerner U, Becker CE: Coma, hyperthermia, and bleeding associated with massive LSD overdose, a report of eight cases. *Clin Toxicol* 8: 191, 1975.
- Halpern JH, Pope HG Jr: Hallucinogen persisting perception disorder: what do we know after 50 years? *Drug Alcohol Depend* 69: 109, 2003.
- Lott JP, Marlowe DB, Forman RF: Availability of websites offering to sell psilocybin spores and psilocybin. *J Psychoactive Drugs* 41: 305, 2009.
- Barbee G, Berry-Caban C, Barry J, Borys D, Ward J, Salyer S: Analysis of mushroom exposures in Texas requiring hospitalization, 2005-2006. *J Med Toxicol* 5: 59, 2009.
- Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX: Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. *Psychopharmacology (Berl)* 172: 145, 2004.
- Bickel M, Ditting T, Watz H, et al: Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse. *Eur J Emerg Med* 12: 306, 2005.
- Frank H, Zilker T, Kirchmair M, et al: Acute renal failure by ingestion of *Cortinarius* species confounded with psychoactive mushrooms: a case series and literature survey. *Clin Nephrol* 71: 557, 2009.
- Halpern JH: Hallucinogens and dissociative agents naturally growing in the United States. *Pharmacol Ther* 102: 131, 2004.
- Carstairs SD, Cantrell FL: Peyote and mescaline exposures: a 12-year review of a statewide poison center database. *Clin Toxicol (Phila)* 48: 350, 2010.
- CDC: Ecstasy overdoses at a New Year's Eve rave—Los Angeles, California, 2010. *MMWR Morb Mortal Wkly Rep* 59: 677, 2010.
- Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F: Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. *Mol Neurobiol* 39: 210, 2009.
- Jansen KL, Theron L: Ecstasy (MDMA), methamphetamine, and date rape (drug-facilitated sexual assault): a consideration of the issues. *J Psychoactive Drugs* 38: 1, 2006.
- Kaye S, Darke S, Dufloy J: Methyleneiodiomethamphetamine (MDMA)-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. *Drug Alcohol Depend* 104: 254, 2009.
- Shenouda SK, Carvalho F, Varner KJ: The cardiovascular and cardiac actions of ecstasy and its metabolites. *Curr Pharm Biotechnol* 11: 470, 2010.
- Sarkar S, Schmued L: Neurotoxicity of ecstasy (MDMA): an overview. *Curr Pharm Biotechnol* 11: 460, 2010.
- Chang SH, Lai TI, Chen WJ, Fang CC: MDMA-induced acute pulmonary edema in a patient without other organ dysfunction. *Am J Emerg Med* 24: 734, 2006.
- Campbell GA, Rosner MH: The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. *Clin J Am Soc Nephrol* 3: 1852, 2008.
- Rosenson J, Smollin C, Sporer KA, Blanc P, Olson KR: Patterns of ecstasy-associated hyponatremia in California. *Ann Emerg Med* 49: 164, 2007.
- Patel MM, Belson MG, Longwater AB, Olson KR, Miller MA: Methyleneiodiomethamphetamine (ecstasy)-related hyperthermia. *J Emerg Med* 29: 451, 2005.
- Ben-Abraham R, Szold O, Rudick V, Weinbroum AA: 'Ecstasy' intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. *Eur J Emerg Med* 10: 309, 2003.
- Turillazzi E, Riezzo I, Neri M, Bello S, Fineschi V: MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings. *Curr Pharm Biotechnol* 11: 500, 2010.
- Oesterheld JR, Armstrong SC, Cozza KL: Ecstasy: pharmacodynamic and pharmacokinetic interactions. *Psychosomatics* 45: 84, 2004.
- Halpern JH, Sherwood AR, Hudson JI, Gruber S, Kozin D, Pope HG Jr: Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. *Addiction* 106: 777, 2011.
- Hall AP, Henry JA: Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. *Br J Anaesth* 96: 678, 2006.
- Bordo DJ, Dorfman MA: Ecstasy overdose: rapid cooling leads to successful outcome. *Am J Emerg Med* 22: 326, 2004.
- Moon J, Cros J: Role of dantrolene in the management of the acute toxic effects of Ecstasy (MDMA). *Br J Anaesth* 99: 146, 2007.
- Duffy MR, Ferguson C: Role of dantrolene in treatment of heat stroke associated with Ecstasy ingestion. *Br J Anaesth* 98: 148, 2007.
- Grunau BE, Wiens MO, Brubacher JR: Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. *CJEM* 12: 435, 2010.
- Mugele J, Nanagas KA, Tormoehlen LM: Serotonin syndrome associated with MDPV use: a case report. *Ann Emerg Med* January 9, 2012. [Epub ahead of print]
- U.S. Drug Enforcement Administration Office of Diversion Control. National Forensic Laboratory Information System Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2009-2010. Springfield, VA. U.S. Drug Enforcement Administration Office of Diversion Control; September 2011.
- U.S. Centers for Disease Control and Prevention. Emergency department visits after use of a drug sold as "bath salts"—Michigan, November 13, 2010-March 31, 2011. *MMWR Morb Mortal Wkly Rep* 60: 624, 2011.
- Prosser JM, Nelson LS: The toxicology of bath salts: a review of synthetic cathinones. *J Med Toxicol* 8: 33, 2012.
- Rosenbaum CD, Carreiro SP, Babu KM: Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, *Salvia divinorum*, methoxetamine, and piperazines. *J Med Toxicol* 8: 15, 2012.
- Wood DM, Davies S, Puchnarewicz M, et al: Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. *J Med Toxicol* 6: 327, 2010.
- Ross EA, Watson M, Goldberger B: "Bath salts" intoxication. *N Engl J Med* 365: 967, 2011.
- Maskell PD, De Paoli G, Seneviratne C, Pounder DJ: Mephedrone (4-methylmethcathinone)-related deaths. *J Anal Toxicol* 35: 188, 2011.
- Schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. *Fed Regis* 76: 65371, 2011.
- Hoiseith G, Hjeltnelund K, Bachs L: [Phencyclidine—angel dust]. *Tidsskr Nor Laegeforen* 125: 2775, 2005.
- O'Shea B: Phencyclidine, ketamine, and khat phencyclidine (PCP, DOA, 'angel dust', 'crystal', 'hog'). *Ir Med J* 93: 185, 2005.
- McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA: Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. *Ann Emerg Med* 10: 237, 1981.
- McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA: Acute phencyclidine intoxication: clinical patterns, complications, and treatment. *Ann Emerg Med* 10: 290, 1981.
- Milhorn HT Jr: Diagnosis and management of phencyclidine intoxication. *Am Fam Physician* 43: 1293, 1991.
- Eastman JW, Cohen SN: Hypertensive crisis and death associated with phencyclidine poisoning. *JAMA* 231: 1270, 1975.
- Stein GY, Fradin Z, Ori Y, Singer P, Korobko Y, Zeidman A: Phencyclidine-induced multi-organ failure. *Is Med Assoc J* 7: 535, 2005.
- Simpson GM, Khajawall AM, Alatorre E, Staples FR: Urinary phencyclidine excretion in chronic abusers. *J Toxicol Clin Toxicol* 19: 1051, 1982.
- Devane WA, Hanus L, Breuer A, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258: 1946, 1992.
- Sinclair CF, Foushee HR, Pevar JS 3rd, Scarinci IC, Carroll WR: Patterns of blunt use among rural young adult African-American men. *Am J Prev Med* 42: 61, 2012.
- Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry* 28: 849, 2004.
- Aryana A, Williams MA: Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? *Int J Cardiol* 118: 141, 2007.
- Pratap B, Korniyenko A: Toxic effects of marijuana on the cardiovascular system. *Cardiovasc Toxicol* December 23, 2011. [Epub ahead of print]
- McGuinness TM: Update on marijuana. *J Psychosoc Nurs Ment Health Serv* 47: 19, 2009.
- Reece AS: Chronic toxicology of cannabis. *Clin Toxicol (Phila)* 47: 517, 2009.
- Sontineni SP, Chaudhary S, Sontineni V, Lanspa SJ: Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognized manifestation of chronic cannabis abuse. *World J Gastroenterol* 15: 1264, 2009.
- Wallace EA, Andrews SE, Garmany CL, Jelley MJ: Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. *South Med J* 104: 659, 2011.
- Dackis CA, Pottash AL, Annitto W, Gold MS: Persistence of urinary marijuana levels after supervised abstinence. *Am J Psychiatry* 139: 1196, 1982.

70. Atwood BK, Huffman J, Straiker A, Mackie K: JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. *Br J Pharmacol* 160: 585, 2010.
71. Schneir AB, Cullen J, Ly BT: "Spice" girls: synthetic cannabinoid intoxication. *J Emerg Med* 40: 296, 2011.
72. Hudson S, Ramsey J: The emergence and analysis of synthetic cannabinoids. *Drug Test Anal* 3: 466, 2011.
73. Wells DL, Ott CA: The "new" marijuana. *Ann Pharmacother* 45: 414, 2011.
74. Every-Palmer S: Synthetic cannabinoid JWH-018 and psychosis: an explorative study. *Drug Alcohol Depend* 117: 152, 2011.
75. Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I. *Fed Regist* 76: 11075, 2011.
76. Corazza O, Schifano F, Farre M, et al: Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. *Curr Clin Pharmacol* 6: 125, 2011.
77. Wood DM, Looker JJ, Shaikh L, et al: Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. *J Med Toxicol* 5: 226, 2009.
78. Andreasen MF, Telving R, Birkler RI, Schumacher B, Johannsen M: A fatal poisoning involving Bromo-Dragonfly. *Forensic Sci Int* 183: 91, 2009.
79. Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P: The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. *Clin Toxicol (Phila)* 49: 131, 2011.
80. Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI: Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperazine (BZP). *J Med Toxicol* 4: 254, 2008.
81. Elliott S, Smith C: Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. *J Anal Toxicol* 32: 172, 2008.
82. Halpern JH, Pope HG Jr: Hallucinogens on the Internet: a vast new source of underground drug information. *Am J Psychiatry* 158: 481, 2001.
83. Babu KM, McCurdy CR, Boyer EW: Opioid receptors and legal highs: *Salvia divinorum* and Kratom. *Clin Toxicol (Phila)* 46: 146, 2008.
84. Prisinzano TE: Psychopharmacology of the hallucinogenic sage *Salvia divinorum*. *Life Sci* 78: 527, 2005.
85. Dalgarno P: Subjective effects of *Salvia divinorum*. *J Psychoactive Drugs* 39: 143, 2007.
86. Vohra R, Seefeld A, Cantrell FL, Clark RF: *Salvia divinorum*: exposures reported to a statewide poison control system over 10 years. *J Emerg Med* 40: 643, 2011.
87. Hitt M, Ettinger DD: Toad toxicity. *N Engl J Med* 314: 1517, 1986.
88. Gowda RM, Cohen RA, Khan IA: Toad venom poisoning: resemblance to digoxin toxicity and therapeutic implications. *Heart* 89: e14, 2003.
89. Kostakis C, Byard RW: Sudden death associated with intravenous injection of toad extract. *Forensic Sci Int* 188: e1, 2009.
90. Kuo HY, Hsu CW, Chen JH, Wu YL, Shen YS: Life-threatening episode after ingestion of toad eggs: a case report with literature review. *BMJ Case Rep* May 10, 2009. [Epub ahead of print]
91. Brubacher JR, Ravikumar PR, Bania T, Heller MB, Hoffman RS: Treatment of toad venom poisoning with digoxin-specific Fab fragments. *Chest* 110: 1282, 1996.
92. Brubacher JR, Lachmanan D, Ravikumar PR, Hoffman RS: Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. *Toxicol* 37: 931, 1999.
93. Demetriades AK, Wallman PD, McGuiness A, Gavalas MC: Low cost, high risk: accidental nutmeg intoxication. *Emerg Med J* Mar 22: 223, 2005.
94. Vearrier D, Greenberg MI: Anticholinergic delirium following *Datura stramonium* ingestion: implications for the Internet age. *J Emerg Trauma Shock* 3: 303, 2010.
95. Glatstein MM, Alabdulrazzaq F, Garcia-Bournissen F, Scolnik D: Use of physostigmine for hallucinogenic plant poisoning in a teenager: case report and review of the literature. *Am J Ther* September 21, 2010 [Epub ahead of print]
96. Wolff K, Winstock AR: Ketamine: from medicine to misuse. *CNS Drugs* 20: 199, 2006.
97. Jansen KL: A review of the nonmedical use of ketamine: use, users and consequences. *J Psychoactive Drugs* 32: 419, 2000.
98. Weiner AL, Vieira L, McKay CA, Bayer MJ: Ketamine abusers presenting to the emergency department: a case series. *J Emerg Med* 18: 447, 2000.
99. Boyer EW: Dextromethorphan abuse. *Pediat Emer Care* 20: 858, 2004.
100. Wilson MD, Ferguson RW, Mazer ME, Litovitz TL: Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000–2010. *Clin Toxicol (Phila)* 49: 409, 2011.